Nanologica

2.16

SEK

+2.37 %

NICA

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Less than 1K followers

+2.37%

+17.71%

+18.68%

-7.69%

-58.09%

-67.16%

-85.97%

-78.66%

-88.09%

Nanologica is a life science tools company that develops, manufactures and sells advanced consumables to pharmaceutical companies. Nanologica's silica-based products are specially designed for the purification of peptide drugs, such as insulin and GLP-1 analogs. Nanologica operates in a global niche market for medicines for the treatment of diabetes and obesity. Nanologica was founded in 2004 and has its headquarters in Södertälje.

Market cap

190.85M SEK

Turnover

103.59K SEK

Revenue

1.44M

EBIT %

-4,858.33 %

P/E

-

Dividend yield-%

-

Financial calendar

7.2

2025

Annual report '24

17.4

2025

Interim report Q1'25

22.5

2025

General meeting '25

ShowingAll content types

Regulatory press release22 hours ago

Change of Dates for Year-End Report 2024 for Nanologica AB

Regulatory press release1/14/2025, 9:41 AM

Nanologica Receives Order of NLAB Saga® Worth appx SEK 8.5 Million from Recurring Customer in China

Regulatory press release12/3/2024, 2:37 PM

Nanologica Receives Order on NLAB Saga® Valued at approx SEK 1,9 Million from Returning Customer in China

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release11/29/2024, 9:05 AM

Number of Shares and Votes in Nanologica AB (publ)

Press release11/12/2024, 4:53 PM

Redeye: Nanologica Q3 2024 - Poised for harvest season?

Regulatory press release11/11/2024, 2:45 PM

Nanologica Announces Nomination Committee for the Annual General Meeting 2025

Regulatory press release11/8/2024, 7:10 AM

Interim Report Q3 2024 Nanologica AB (publ)

Regulatory press release10/31/2024, 12:54 PM

Number of Shares and Votes in Nanologica AB (publ)

Regulatory press release10/30/2024, 9:21 AM

Nanologica's Rights Issue Registered - Conversion of BTU to Shares and warrants

Regulatory press release10/16/2024, 5:03 PM

Nanologica Announces Outcome of Rights Issue

Regulatory press release10/8/2024, 2:17 PM

Nanologica Publishes supplementary Prospectus in Connection with Rights Issue

Regulatory press release10/4/2024, 11:55 AM

Nanologica Receives Supplementary Order Worth approximately SEK 1.9 Million from Returning Customer in China

Regulatory press release9/26/2024, 1:28 PM

Nanologica Publishes Prospectus in Connection with Rights Issue

Regulatory press release9/26/2024, 7:52 AM

Nanologica Receives Order for NLAB Saga® Worth approx. SEK 3,7 Million from Returning Customer in China

Regulatory press release9/23/2024, 1:07 PM

Bulletin from the Extraordinary General Meeting of Nanologica AB (publ)

Press release9/2/2024, 5:02 PM

Clarification to the PR Regarding Proposal for Change in the Board of Directors for Nanologica AB (publ)

Regulatory press release9/2/2024, 2:18 PM

Proposal for Change in the Board of Directors of Nanologica AB (publ)

Regulatory press release8/29/2024, 6:00 AM

NOTICE OF EXTRAORDINARY GENERAL MEETING IN NANOLOGICA AB (PUBL)

Regulatory press release8/29/2024, 5:45 AM

NANOLOGICA RESOLVES ON A FULLY UNDERWRITTEN RIGHTS ISSUE OF UNITS OF APPROX. SEK 99.4 MILLION, AN OVER-ALLOTMENT ISSUE OF UP TO SEK 20 MILLION, AND RAISES BRIDGE LOANS OF SEK 15 MILLION

Press release7/8/2024, 8:28 AM

Redeye: Nanologica Q2 2024 - Improvement in production

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.